$21.79
3.50% yesterday
Nasdaq, Nov 15, 10:00 pm CET
ISIN
US0887861088
Symbol
BCYC
Sector
Industry

Bicycle Therapeutics Plc Stock price

$21.79
-5.30 19.56% 1M
-0.57 2.55% 6M
+3.71 20.52% YTD
+6.40 41.59% 1Y
-39.35 64.36% 3Y
+12.40 131.95% 5Y
+7.79 55.64% 10Y
Nasdaq, Closing price Fri, Nov 15 2024
-0.79 3.50%
ISIN
US0887861088
Symbol
BCYC
Sector
Industry

Key metrics

Market capitalization $1.50b
Enterprise Value $624.09m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 16.88
P/S ratio (TTM) P/S ratio 40.68
P/B ratio (TTM) P/B ratio 1.81
Revenue growth (TTM) Revenue growth 48.46%
Revenue (TTM) Revenue $36.97m
EBIT (operating result TTM) EBIT $-234.98m
Free Cash Flow (TTM) Free Cash Flow $-204.41m
Cash position $890.86m
EPS (TTM) EPS $-3.30
P/E forward negative
P/S forward 41.48
EV/Sales forward 18.06
Short interest 7.41%
Show more

Is Bicycle Therapeutics Plc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

Bicycle Therapeutics Plc Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a Bicycle Therapeutics Plc forecast:

12x Buy
80%
3x Hold
20%

Analyst Opinions

15 Analysts have issued a Bicycle Therapeutics Plc forecast:

Buy
80%
Hold
20%

Financial data from Bicycle Therapeutics Plc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
37 37
48% 48%
100%
- Direct Costs 7.16 7.16
14% 14%
19%
30 30
60% 60%
81%
- Selling and Administrative Expenses 51 51
20% 20%
139%
- Research and Development Expense 206 206
27% 27%
558%
-228 -228
22% 22%
-616%
- Depreciation and Amortization 7.16 7.16
14% 14%
19%
EBIT (Operating Income) EBIT -235 -235
21% 21%
-636%
Net Profit -167 -167
3% 3%
-452%

In millions USD.

Don't miss a Thing! We will send you all news about Bicycle Therapeutics Plc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Bicycle Therapeutics Plc Stock News

Neutral
Business Wire
4 days ago
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that management will participate in a fireside chat at the Jefferies London Healthcare Conference on Nov. 19, 2024, at 10:30 a.m. GMT. A live webc...
Positive
Seeking Alpha
8 days ago
Today, we revisit Bicycle Therapeutics plc, a clinical-stage biopharma firm, that has intriguing potential and focuses on developing medicines for unmet needs. The company is advancing several candidates within its pipeline and is well-funded into mid-2027.  The stock also continues to enjoy strong analyst firm support. An updated analysis of Bicycle Therapeutics follows in the paragraphs below.
Neutral
Business Wire
14 days ago
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), today announced that on November 1, 2024, the Compensation Committee of the company's Board of Directors granted to twelve new employees inducement awards consisting of non-qualified share options to purchase an aggregate of 56,700 ordinary shares. These awards were made under Bicycle Therapeutics' 2024 Induc...
More Bicycle Therapeutics Plc News

Company Profile

Bicycle Therapeutics Plc is a holding company, which engages in the development of biopharmaceuticals. It focuses on developing a novel class of medicines, which the company refers to as bicycles, for diseases that are underserved by existing therapeutics. The firm utilizes its novel and proprietary phage display screening platform to identify bicycles. Its portfolio includes internal product candidates that are directed to oncology applications. The company was founded by Gregory Winter, John Tite, and Christian Heinis in 2009 and is headquartered in Cambridge, the United Kingdom.

Head office United Kingdom
CEO Kevin Lee
Employees 284
Founded 2009
Website bicycletherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today